AHA · Chicago · 2026-11-06 – 2026-11-09
AHA Scientific Sessions 2026
1 des 21 essais Late-Breaking Science avec résultatLes résultats sont sous embargo jusqu'à chaque présentation et apparaissent ici dès leur publication.
ven. 6 nov.
sam. 7 nov.
LBS.01 The Dr. Eugene Braunwald Late-Breaking Science Session: Translating Science into Prevention: Lessons from Landmark Trials
08:35–09:50 (America/Chicago) · Center Stage, North Hall, Level 3- 08:35ZEUSÉtude cliniquePrimary Report of the Ziltivekimab Cardiovascular Outcomes Trial (ZEUS)Présentation sam., 08:35
- 08:50Lp(a)HORIZON Essai cléCardiologie · Lipides · Lipoprotéine(a)Chez 8.323 patients atteints d'une maladie cardiovasculaire avérée et ayant une Lp(a) ≥70 mg/dL, le pélacarsen 80 mg par mois n'a pas réduit les décès cardiovasculaires, infarctus du myocarde, AVC ou revascularisations urgentes par rapport au placebo.Lire →
- 09:00Lp(a)HORIZON extended analysesÉtude observationnelleExtended Analyses of Cardiovascular Outcomes With Pelacarsen Treatment in the Lp(a)Horizon TrialPrésentation sam., 09:00
LBS.02 Late-breaking Science: Treating the Clot or Controlling the Blood Pressure: Improving Outcomes After Stroke
13:45–14:45 (America/Chicago) · Center Stage, North Hall, Level 3- 13:45OCEANIC-STROKE FraminghamÉtude observationnelleOutcomes in the OCEANIC-STROKE Randomized, Placebo-Controlled Trial: FXIa Inhibition by Asundexian in Participants With Non-Cardioembolic Stroke or Transient Ischemic Attack by Non-Laboratory Framingham Risk Score CategoryPrésentation sam., 13:45
- 14:00REDUCEÉtude cliniqueA Randomized Controlled Trial of Spironolactone-Based Blood Pressure Management After StrokePrésentation sam., 14:00
- 14:15OPTIMAL-StrokeÉtude cliniqueIntensive Blood-Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Prior Stroke: The OPTIMAL-Stroke TrialPrésentation sam., 14:15
LBS.03 Late-breaking Science: Hot Topics in CVD Prevention
15:15–16:30 (America/Chicago) · Center Stage, North Hall, Level 3- 15:15STREAMÉtude cliniqueDiscontinuing Statins in Multimorbid Older Adults Without Cardiovascular Disease: A Randomized Non-Inferiority Clinical TrialPrésentation sam., 15:15
- 15:30OPTIMAL-DIABETESÉtude cliniqueIntensive Blood Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Type 2 Diabetes - The OPTIMAL-DIABETES TrialPrésentation sam., 15:30
- 15:45Ez-PAVEÉtude cliniqueStatin-Ezetimibe Combination Therapy versus Statin Monotherapy in Patients With Atherosclerotic Cardiovascular Disease: Pre-Specified Second Randomization of the Ez-PAVE TrialPrésentation sam., 15:45
- 16:00Yoga-CaRe HFÉtude cliniqueYoga-Based Cardiac Rehabilitation in Heart Failure With Reduced Ejection FractionPrésentation sam., 16:00
dim. 8 nov.
LBS.04 Late-breaking Science: Innovations to Optimize Arrhythmia Care
15:30–16:45 (America/Chicago) · Center Stage, North Hall, Level 3- 15:30OptimPacingÉtude cliniqueLeft Bundle Branch Pacing versus Right Ventricular Pacing for Atrioventricular Block: An International Multi-Center Randomized Controlled Trial (OptimPacing Study)Présentation dim., 15:30
- 15:45COAST-AFÉtude cliniqueCharacterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation: COAST-AF Randomized TrialPrésentation dim., 15:45
- 16:00SUPERIORÉtude cliniqueSacubitril/Valsartan for Preventing Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Hypertension: A Multicenter, Randomized Controlled TrialPrésentation dim., 16:00
- 16:15RACE-CARSÉtude cliniqueRandomized Cluster Evaluation of Cardiac ARrest Systems (RACE-CARS) Trial Primary ResultsPrésentation dim., 16:15
lun. 9 nov.
LBS.05 Late-breaking Science: New Frontiers in Cardiometabolic Risk Reduction
08:00–09:15 (America/Chicago) · Center Stage, North Hall, Level 3- 08:00TYDAL-TIMI 78Étude cliniqueTYDAL-TIMI 78: A Randomized Trial of ANGPTL4 Inhibition With MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol ConcentrationsPrésentation lun., 08:00
- 08:15CTX310Étude cliniqueCRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b TrialPrésentation lun., 08:15
- 08:30ATTAIN-OSAÉtude cliniqueOrforglipron for the Treatment of Obstructive Sleep Apnea: Results From Attain-OSAPrésentation lun., 08:30
- 08:45SYNCHRONIZE-CVOTÉtude cliniqueSurvodutide and Cardiovascular Outcomes in Obesity: Results from the SYNCHRONIZE®-CVOT TrialPrésentation lun., 08:45
LBS.06 Late-breaking Science: Artificial Intelligence in the Diagnosis of Cardiovascular Disease
09:45–11:00 (America/Chicago) · Center Stage, North Hall, Level 3- 09:55WATCH-LVÉtude observationnelleConsumer Smartwatch Artificial Intelligence-Enabled Electrocardiogram for Left Ventricular Systolic Dysfunction: Cross-Manufacturer Validation and Serial Home MonitoringPrésentation lun., 09:55
- 10:05PROVAR+Étude observationnelleAI-Enabled Tele-ECG Identifies Structural Heart Disease and Prioritizes Echocardiography in Underserved Populations: The PROVAR+ External Validation StudyPrésentation lun., 10:05
- 10:22AI echo interpretation RCTÉtude cliniqueAI-Assisted Comprehensive Echocardiographic Interpretation—A Blinded, Randomized Controlled TrialPrésentation lun., 10:22